Video

Pharmacotherapy for patients with advanced and metastatic prostate cancer

Launched: June 26, 2018
Length: 19 minutes
Presenter: Dr Andrew Feifer, MD, MPH, FRCSC

Webinar overview: This webinar introduces common drug treatments for advanced and metastatic prostate cancer. Dr Andrew Feifer discusses the role of testosterone and the androgen receptor in the development and growth of prostate cancer. He also discusses the efficacy and side effects of drug-based treatments, including hormone therapy and novel therapies for castration-resistant prostate cancer.

Presenter

Dr Feifer is a urologic oncologist at the Carlo Fidani Cancer Centre at Credit Valley Hospital where he specializes in the management of advanced castrate resistant prostate cancer. He is also an assistant professor of surgery at the University of Toronto and a faculty member at Princess Margaret (University Health Network). Dr Feifer maintains active research interest in urologic oncology outcomes, quality of care in surgery and comparative effectiveness of new surgical techniques.
Dr Andrew Feifer
Dr Andrew Feifer

About Expert Angle

Expert Angle is a webinar series hosted by experts that provides information and support to people living with cancer, cancer survivors and their families. This series is available on demand, which means you can watch the webinars at any time from the comfort of your home.

Votre source de confiance pour des informations fiables sur le cancer

Le soutien des lecteurs comme vous nous permet de continuer à fournir des informations de la plus haute qualité sur plus de 100 types de cancer.

Nous sommes là pour vous garantir un accès facile à des informations fiables sur le cancer, ainsi qu’aux millions de personnes qui visitent ce site Web chaque année. Mais nous ne pouvons pas y arriver seuls.

Chaque don nous permet d’offrir des informations fiables sur le cancer et finance des services de soutien empreints de compassion et des projets de recherche prometteurs. Faites un don dès maintenant, car chaque dollar compte. Nous vous remercions.